Abstract: Among the various aspects of the present disclosure is the provision of conjugate systems and methods of use thereof. In an aspect, the conjugate system includes an adenovirus comprising an exterior surface, and at least one polypeptide comprising a first domain and a second domain, and wherein the exterior surface comprises a peptide tag capable of binding to a binding partner.

Abstract: Provided herein are synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof. Also provided herein are methods of treating and/or preventing Plasmodium infection and/or disease by administering the synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof.

Abstract: Systems and methods for monitoring and controlling delivery of a therapeutic compound to a brain of a subject using FUS-BBBD are disclosed. The method includes treating the brain of the subject with focused ultrasound in combination with microbubbles for blood-brain barrier disruption (FUS-BBBD), administering the therapeutic agent to the subject; and obtaining a map of a concentration of the therapeutic agent delivered to the brain of the subject using passive cavitation imaging (PCI). The delivery of focused sound may be modulated to match the map of the concentration of the therapeutic agent delivered to the brain of the subject to a desired spatial distribution of the therapeutic agent.

Abstract: The present invention is a method or system for acceptance testing and commissioning of a LINAC and treatment planning system (TPS). For a LINAC commissioning, the present invention collects reference data from a fully calibrated LINAC and compares the reference data with machine performance data collected from LINAC. The compared results are analyzed to assess accuracy of the testing LINAC. For a TPS commissioning, the present invention collects standard reference data from standard treatment plans and standard input data and compares the standard reference data with results from standard tests that are performed by a testing treatment plan system. The compares results are analyzed to assess accuracy of the testing treatment plan system.

Abstract: Among the various aspects of the present disclosure is the provision of systems and methods for producing systems and methods for the computational design of CRISPR guide RNAs for strain-specific control of microbiota consortia.

Abstract: Systems and methods for the selection of a treatment for pancreatic adenocarcinoma (PDAC) in a patient in need based on single-cell RNA sequencing data obtained from a tumor biopsy sample obtained prior to treatment are disclosed. Also disclosed are systems and methods for predicting a clinical outcome of a pancreatic adenocarcinoma (PDAC) patient based on the single-cell RNA sequencing data.

Abstract: The present disclosure provides for compositions of, synthetic methods of, and methods for use of dihydrofolate synthase (DHFS) inhibiting agents.

Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods to detect immune system activation and inhibition, including but not limited to a pro-tumor radioresistant tumor microenvironment, including but not limited to overexpressed SERPINB3, and the modulation of this microenvironment with modulators, including but not limited to STAT inhibitors, which can improve radiotherapy in cancer patients.

Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.

Abstract: The present invention is directed to various compounds, compositions, and methods for treating bacterial infections such as urinary tract infections.

Abstract: Solutions having a solvent and a cold atmospheric plasma dissolved in the solvent are described. Methods and systems of forming cold atmospheric plasma (CAP)-containing solutions are also described. A system for producing (CAP)-containing solutions includes a gas source; a plasma generating device having a hollow body fluidically coupled with the gas source, a closed proximal end and an open distal end, the hollow body receiving gas from the gas source, and at least one electrode in or about the hollow body and ionizing the gas to discharge a cold atmospheric plasma (CAP) from the open distal end; and a container for housing a fluid, the open distal end of the plasma generating device in fluid communication with an inner portion of the container. CAP-containing solutions can be used in treatment of cancer cells, infected tissue sterilization, microorganism inactivation, promotion of wound healing, skin regeneration, and blood coagulation, and teeth bleaching/whitening.

Abstract: Systems and methods for virtual reality or augmented reality (VR/AR) visualization of 3D medical images using a VR/AR visualization system are disclosed that includes a computing device operatively coupled to a VR/AR device, which includes a holographic display and at least one sensor. The holographic display is configured to display a holographic image to an operator. The computing device is configured to receive at least one stored 3D image of a subject's anatomy and at least one real-time 3D position of at least one surgical instrument, to register the at least one real-time 3D position of the at least one surgical instrument to correspond to the at least one 3D image of the subject's anatomy, and to generate the holographic image comprising the at least one real-time position of the at least one surgical instrument overlaid on the at least one 3D image of the subject's anatomy.

Abstract: In one aspect, a composition for sustained release of oxygen to a tissue is disclosed that includes at least one core-shell oxygen release microsphere (ORM), wherein the core includes a water-soluble polymer-reactive oxygen species (ROS) complex and the shell includes a biodegradable polymer conjugated to a ROS-scavenging enzyme. In some aspects, the reactive oxygen species includes hydrogen peroxide (H2O2), the ROS-scavenging enzyme includes catalase, the water-soluble polymer includes polyvinylpyrrolidone (PVP), and the biodegradable polymer includes poly(N-isopropylacrylamide-co-2-hydroxyethyl methacrylate-co-acrylate-oligolactide-co-Nacryloxysuccinimide)[poly(NIPAAm-co-HEMA-co-AOLA-co-NAS)].

Abstract: A method for selecting a seed region for use in a seed-based cortical functional mapping method includes providing at least one RSN map of at least one subject, each of the at least one RSN maps comprising a plurality of functional voxels within a brain of each of the at least one subjects, each functional voxel of the plurality of functional voxels associated with a probability of membership in an RSN. A subset of the functional voxels characterizing a contiguous region is selected as the seed region, each functional voxel of the seed region having a probability of membership in the RSN above a threshold value.

Abstract: Methods of using a foot device are disclosed herein. The foot device includes a generally U-shaped portion having an arcuate portion and first and second legs extending from the arcuate portion. Each leg has an end and a relief area disposed adjacent the respective end. A method of using the foot device comprises engaging the arcuate portion with a heel of a foot to form a first point of contact; positioning the relief area of the first leg proximate a fifth metatarsal head of the foot such that the fifth metatarsal head drops to form a second point of contact; and positioning the relief area of the second leg proximate a first metatarsal head of the foot such that the first metatarsal head drops to form a third point of contact, wherein the first, second, and third points of contact form a triangle-shaped contact surface.

Abstract: Provided herein are methods for the treatment of bone disorders that are associated with kidney disease wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification.

Abstract: A goggle system is provided. The goggle system includes a computing device, a goggle device configured to be worn by a user and including a detector configured to simultaneously acquire image data of a subject in a first image mode and a second image mode, at least one eye assembly configured to display at least one of an image in the first image mode, an image in the second image mode, and a hybrid image including pixels of image data from the first image mode and pixels of image data from the second image mode, and a communications module configured to transmit acquired image data from the goggle device to the computing device.

Abstract: A thruster has a first stage and a second stage. The first stage is a plasma source that outputs a plasma. The second stage is an accelerator. In one embodiment, the second stage is a plasma accelerator that accelerates the plasma. In another embodiment, the second stage is an ion accelerator that accelerates the ions from the plasma.

Abstract: Compositions comprising small molecule mitofusin agonists are described. The mitofusin modulating agents are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (Mfn1) and/or mitofusin 2 (Mfn2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that regulate mitochondrial function are also described.

Abstract: The present invention is a method or system for acceptance testing and commissioning of a LINAC and treatment planning system (TPS). For a LINAC commissioning, the present invention collects reference data from a fully calibrated LINAC and compares the reference data with machine performance data collected from LINAC. The compared results are analyzed to assess accuracy of the testing LINAC. For a TPS commissioning, the present invention collects standard reference data from standard treatment plans and standard input data and compares the standard reference data with results from standard tests that are performed by a testing treatment plan system. The compares results are analyzed to assess accuracy of the testing treatment plan system.